Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

NCT02143830 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT02143830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02143830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2014
Completion date
December 31, 2028
Enrollment
70 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia (aml), fanconi anemia, myelodysplastic syndrome (mds), severe marrow failure